Zacks Investment Research cut shares of CorMedix (NYSEAMERICAN:CRMD) from a buy rating to a sell rating in a research report report published on Wednesday.
According to Zacks, “CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey. “
Separately, HC Wainwright set a $4.00 target price on CorMedix and gave the company a buy rating in a research note on Monday, April 2nd.
CRMD opened at $0.22 on Wednesday. CorMedix has a 1 year low of $0.17 and a 1 year high of $1.46.
A number of hedge funds and other institutional investors have recently modified their holdings of CRMD. Virtu Financial LLC boosted its holdings in CorMedix by 126.4% in the fourth quarter. Virtu Financial LLC now owns 226,748 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 126,610 shares in the last quarter. Spinnaker Capital LLC acquired a new stake in CorMedix in the fourth quarter worth about $202,000. Finally, Vanguard Group Inc. boosted its holdings in CorMedix by 3.0% in the second quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 35,148 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: “CorMedix (CRMD) Rating Lowered to Sell at Zacks Investment Research” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/cormedix-crmd-rating-lowered-to-sell-at-zacks-investment-research.html.
CorMedix Company Profile
CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.
Get a free copy of the Zacks research report on CorMedix (CRMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.